213 related articles for article (PubMed ID: 23429537)
1. Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1.
Miura K; Herrera R; Diouf A; Zhou H; Mu J; Hu Z; MacDonald NJ; Reiter K; Nguyen V; Shimp RL; Singh K; Narum DL; Long CA; Miller LH
Infect Immun; 2013 May; 81(5):1491-501. PubMed ID: 23429537
[TBL] [Abstract][Full Text] [Related]
2. In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized.
Miura K; Zhou H; Muratova OV; Orcutt AC; Giersing B; Miller LH; Long CA
Infect Immun; 2007 Dec; 75(12):5827-36. PubMed ID: 17923516
[TBL] [Abstract][Full Text] [Related]
3. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.
Kennedy MC; Wang J; Zhang Y; Miles AP; Chitsaz F; Saul A; Long CA; Miller LH; Stowers AW
Infect Immun; 2002 Dec; 70(12):6948-60. PubMed ID: 12438374
[TBL] [Abstract][Full Text] [Related]
4. Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines.
Terheggen U; Drew DR; Hodder AN; Cross NJ; Mugyenyi CK; Barry AE; Anders RF; Dutta S; Osier FH; Elliott SR; Senn N; Stanisic DI; Marsh K; Siba PM; Mueller I; Richards JS; Beeson JG
BMC Med; 2014 Oct; 12():183. PubMed ID: 25319190
[TBL] [Abstract][Full Text] [Related]
5. Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naïve adults.
Remarque EJ; Roestenberg M; Younis S; Walraven V; van der Werff N; Faber BW; Leroy O; Sauerwein R; Kocken CH; Thomas AW
PLoS One; 2012; 7(6):e38898. PubMed ID: 22768052
[TBL] [Abstract][Full Text] [Related]
6. Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity.
Kusi KA; Faber BW; Thomas AW; Remarque EJ
PLoS One; 2009 Dec; 4(12):e8110. PubMed ID: 19956619
[TBL] [Abstract][Full Text] [Related]
7. Defining the antigenic diversity of Plasmodium falciparum apical membrane antigen 1 and the requirements for a multi-allele vaccine against malaria.
Drew DR; Hodder AN; Wilson DW; Foley M; Mueller I; Siba PM; Dent AE; Cowman AF; Beeson JG
PLoS One; 2012; 7(12):e51023. PubMed ID: 23227229
[TBL] [Abstract][Full Text] [Related]
8. Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response.
Kusi KA; Faber BW; Riasat V; Thomas AW; Kocken CH; Remarque EJ
PLoS One; 2010 Nov; 5(11):e15391. PubMed ID: 21082025
[TBL] [Abstract][Full Text] [Related]
9. A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits.
Remarque EJ; Faber BW; Kocken CH; Thomas AW
Infect Immun; 2008 Jun; 76(6):2660-70. PubMed ID: 18378635
[TBL] [Abstract][Full Text] [Related]
10. Allelic diversity and naturally acquired allele-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 in Kenya.
Osier FH; Weedall GD; Verra F; Murungi L; Tetteh KK; Bull P; Faber BW; Remarque E; Thomas A; Marsh K; Conway DJ
Infect Immun; 2010 Nov; 78(11):4625-33. PubMed ID: 20732997
[TBL] [Abstract][Full Text] [Related]
11. Non-apical membrane antigen 1 (AMA1) IgGs from Malian children interfere with functional activity of AMA1 IgGs as judged by growth inhibition assay.
Miura K; Perera S; Brockley S; Zhou H; Aebig JA; Moretz SE; Miller LH; Doumbo OK; Sagara I; Dicko A; Ellis RD; Long CA
PLoS One; 2011; 6(6):e20947. PubMed ID: 21695140
[TBL] [Abstract][Full Text] [Related]
12. Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine.
Ouattara A; Mu J; Takala-Harrison S; Saye R; Sagara I; Dicko A; Niangaly A; Duan J; Ellis RD; Miller LH; Su XZ; Plowe CV; Doumbo OK
Malar J; 2010 Jun; 9():175. PubMed ID: 20565971
[TBL] [Abstract][Full Text] [Related]
13. Identification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbits.
Younis S; Faber BW; Kocken CHM; Remarque EJ
BMC Immunol; 2019 Jul; 20(1):25. PubMed ID: 31362695
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
Malkin EM; Diemert DJ; McArthur JH; Perreault JR; Miles AP; Giersing BK; Mullen GE; Orcutt A; Muratova O; Awkal M; Zhou H; Wang J; Stowers A; Long CA; Mahanty S; Miller LH; Saul A; Durbin AP
Infect Immun; 2005 Jun; 73(6):3677-85. PubMed ID: 15908397
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV; Biswas S; Pillai CR; Saxena RK
Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
[TBL] [Abstract][Full Text] [Related]
16. Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with Plasmodium falciparum apical membrane antigen 1 vaccine candidate FMP2.1/AS02
Berry AA; Gottlieb ER; Kouriba B; Diarra I; Thera MA; Dutta S; Coulibaly D; Ouattara A; Niangaly A; Kone AK; Traore K; Tolo Y; Mishcherkin V; Soisson L; Diggs CL; Blackwelder WC; Laurens MB; Sztein MB; Doumbo OK; Plowe CV; Lyke KE
Malar J; 2019 Jan; 18(1):13. PubMed ID: 30658710
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O;
Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345
[TBL] [Abstract][Full Text] [Related]
18. Diversity covering AMA1-MSP119 fusion proteins as malaria vaccines.
Faber BW; Younis S; Remarque EJ; Rodriguez Garcia R; Riasat V; Walraven V; van der Werff N; van der Eijk M; Cavanagh DR; Holder AA; Thomas AW; Kocken CH
Infect Immun; 2013 May; 81(5):1479-90. PubMed ID: 23429538
[TBL] [Abstract][Full Text] [Related]
19. Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay.
Miura K; Zhou H; Diouf A; Moretz SE; Fay MP; Miller LH; Martin LB; Pierce MA; Ellis RD; Mullen GE; Long CA
Clin Vaccine Immunol; 2009 Jul; 16(7):963-8. PubMed ID: 19439523
[TBL] [Abstract][Full Text] [Related]
20. Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1.
Faber BW; Remarque EJ; Morgan WD; Kocken CH; Holder AA; Thomas AW
Infect Immun; 2007 Dec; 75(12):5947-55. PubMed ID: 17938224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
